Click on image to view ad details and full-size version on AdPharm.

To see all of this brand’s ads on AdPharm, click here

Click on image to view ad details and full-size version on AdPharm

To see all of this brand’s ads on AdPharm, click here

Click on thumbnail to view the commercial on AdPharm

[Voice-Over]
Aaaah! Fall. A season synonymous with vibrant colors. Fresh air. Walking in the woods. Bird watching. And running!
Whatever you’re into, Celebrex wishes you a happy season.

Ask your doctor about Celebrex.

Agency: Taxi

Brand name: Celebrex
Generic name/category: Celecoxib, Pyrazoles, COX-2 inhibitors, Antineoplastic drugs, non-steroidal anti-inflammatory drug (NSAID)
Company: Pfizer
Country/Market: Canada, North America
Indication(s)/use: osteoarthritis (OA), rheumatoid arthritis (RA), acute pain and Ankylosing Spondilitis (AS)
Target: Consumers (DTC)
Tagline: Celebrex wishes you a happy season
Medium: TV commercial
Size/duration: 30 seconds
Publication/Aired: 2009

To see all of this brand’s ads on AdPharm, click here

Click on thumbnail to view the full-size ad on AdPharm

Introducing Simponi.
The first monthly SC anti TNF a…

… all in one

-Proven efficacy in RA, As and PsA
-SmartJect autoinjector – designed to be patient-friendly
-Low injection volume (0.5 mL)
-Human lgG1k monoclonal antibody
-Patient support through the BioAdvantage Network

Monthly Simponi

The Simponi SmartJect autoinjector. Designed to be arthritis-patient-friendly.

Brand name: Simponi
Generic name/category: Golimumab, Monoclonal antibodies, TNF-alpha inhibitors
Company: Schering-Plough
Country/Market: Canada, North America
Indication(s)/use: Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondilitis (AS)
Target: Healthcare Professionals (HCP)
Tagline: all in one
Medium: Print ad
Size/duration: three-page spread
Publication/Aired: NEJM – September 24, 2009

To see all of this brand’s ads on AdPharm, click here

Take control again

In moderate to severe Crohn’s disease, demonstrated to sustain power, sustain remission.

Adalimumab (brand name HUMIRA) is the third TNF inhibitor, after infliximab and etanercept, to be approved in the United States. Like infliximab and etanercept, adalimumab binds to TNFa, preventing it from activating TNF receptors; adalimumab was constructed from a fully human monoclonal antibody, while infliximab is a mouse-human chimeric antibody and etanercept is a TNF receptor-IgG fusion protein. TNFa inactivation has proven to be important in downregulating the inflammatory reactions associated with autoimmune diseases. As of 2008 adalimumab has been approved by the FDA for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis.

Humira (brand name is an abbreviation of "Human Monoclonal Antibody in Rheumatoid Arthritis") is marketed in both preloaded 0.8 ml syringes and also in preloaded pen devices (called Humira Pen), both injected subcutaneously, typically by the patient at home. It cannot be administered orally, because the digestive system would destroy the drug.

Humira’s manufacturer is Abbott Laboratories. – Wikipedia

CMAJ April 2009

More Humira ads on AdPharm

La douleur est un voleur.

Elle peut priver le patient d’une vie sans douleur.
L’AINS le plus délivré au Canada tel que prescrit par les omnipraticiens, les rhumatologues, les gastroentérologues et les cardiologues.

Celecoxib (INN) is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer. It has the brand name Celebrex and Celebra (in other countries) for arthritis and Onsenal for polyps. Celecoxib is available by prescription in capsule form.

Celecoxib is licensed for use in osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce the number of colon and rectal polyps in patients with familial adenomatous polyposis. It was originally intended to relieve pain while minimizing the gastrointestinal adverse effects usually seen with conventional NSAIDs. In practice, its primary indication is in patients who need regular and long term pain relief: there is probably no advantage to using celecoxib for short term or acute pain relief over conventional NSAIDs. In addition, the pain relief offered by celecoxib is similar to that offered by paracetamol.– Wikipedia

Le Clinicien March 2009

More Celebrex ads on AdPharm